High value science-based consumer products! In an interview before his exit from Canopy, Bruce had responded to an interview question regarding the dropping price/gram of mj. His answer was that from his and Canopy's perspective that this kind of outcome would be consistent with their vision. Essentially, the greatest returns would be created by the development of high value science-based consumer/medical products. So why get overly committed and bogged down in the costly, lower return, grunt work of growing in every jurisdiction world-wide. That aspect of the vertical chain can be left to others and leveraged through partnerships. Ultimately having the most robust research and development stream stemming from their industry leading vault of 400+patents will produce the outcomes and returns investors are looking and willing to pay for. Just food for thought. GLTA